Home LiteratureArticle Details
PMID: 20147902 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review

Breast and prostate cancer: more similar than different.

Nature reviews. Cancer ·Vol. 10 ·No. 3 ·2010-03-00 ·Pages 205-12

Risbridger GP, Davis ID, Birrell SN, Tilley WD

Abstract

Breast cancer and prostate cancer are the two most common invasive cancers in women and men, respectively. Although these cancers arise in organs that are different in terms of anatomy and physiological function both organs require gonadal steroids for their development, and tumours that arise from them are typically hormone-dependent and have remarkable underlying biological similarities. Many of the recent advances in understanding the pathophysiology of breast and prostate cancers have paved the way for new treatment strategies. In this Opinion article we discuss some key issues common to breast and prostate cancer and how new insights into these cancers could improve patient outcomes.

MeSH Terms
Breast Neoplasms/drug therapy,genetics,immunology,metabolism Female Hormones/metabolism,therapeutic use Humans Male Prostatic Neoplasms/drug therapy,genetics,immunology,metabolism
Chemicals
Hormones
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Risbridger Gail P
Department of Anatomy & Developmental Biology, Monash University Clayton Campus, Melbourne 3800, Victoria, Australia. Gail.Risbridger@med.monash.edu.au
Davis Ian D
Birrell Stephen N
Tilley Wayne D
References (126)
126 references, click to expand
  1. Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway.
    Biochem Biophys Res Commun. 2002 Jan 11;290(1):249-55 PMID: 11779161
  2. The evolving role of oestrogen receptor beta in clinical breast cancer.
    Breast Cancer Res. 2008;10(5):111 PMID: 18831727
  3. Estrogen and progesterone receptor proteins in breast cancer.
    Biochim Biophys Acta. 1979 Dec 19;560(4):457-86 PMID: 391286
  4. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins.
    J Immunol. 2004 May 1;172(9):5467-77 PMID: 15100288
  5. The use of dendritic cells in cancer therapy.
    Lancet Oncol. 2001 Jun;2(6):343-53 PMID: 11905751
  6. BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated transcription.
    Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7201-6 PMID: 12756300
  7. Prostatic tumor stroma: a key player in cancer progression.
    Curr Cancer Drug Targets. 2008 Sep;8(6):490-7 PMID: 18781895
  8. Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer.
    FASEB J. 2007 Aug;21(10):2285-93 PMID: 17413000
  9. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway.
    Cell. 2006 Feb 10;124(3):615-29 PMID: 16469706
  10. Physiological action of progesterone in target tissues.
    Endocr Rev. 1997 Aug;18(4):502-19 PMID: 9267762
  11. Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia.
    Endocrinology. 2007 Feb;148(2):566-74 PMID: 17068134
  12. A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study.
    Prostate. 2006 Oct 1;66(14):1556-64 PMID: 16921508
  13. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.
    Cancer. 2009 Aug 15;115(16):3670-9 PMID: 19536890
  14. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole.
    Cancer Res. 1997 Jun 1;57(11):2109-11 PMID: 9187104
  15. History of aromatase: saga of an important biological mediator and therapeutic target.
    Endocr Rev. 2009 Jun;30(4):343-75 PMID: 19389994
  16. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.
    Cancer Cell. 2008 Feb;13(2):91-104 PMID: 18242510
  17. Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells.
    Mol Cell Biol. 2000 Apr;20(7):2581-91 PMID: 10713180
  18. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1.
    J Clin Pathol. 2004 Oct;57(10):1069-74 PMID: 15452162
  19. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines.
    Breast Cancer Res. 2008;10(6):R95 PMID: 19014637
  20. Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor.
    Breast Cancer. 2010 Oct;17(4):254-60 PMID: 19685269
  21. PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.
    Urology. 2009 May;73(5):935-9 PMID: 19328538
  22. Progestins regulate genes that can elicit both proliferative and antiproliferative effects in breast cancer cells.
    Oncol Rep. 2008 Jun;19(6):1627-34 PMID: 18497975
  23. Exemestane: a review of its use in postmenopausal women with breast cancer.
    Drugs. 2009;69(7):889-918 PMID: 19441873
  24. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Cochrane Database Syst Rev. 2008 Oct 08;(4):CD004562 PMID: 18843661
  25. Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer.
    J Steroid Biochem. 1987 Oct;28(4):379-84 PMID: 2444770
  26. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer.
    Cancer Res. 2001 Jan 15;61(2):423-7 PMID: 11212224
  27. Cancer immunoediting: from immunosurveillance to tumor escape.
    Nat Immunol. 2002 Nov;3(11):991-8 PMID: 12407406
  28. New selective estrogen and androgen receptor modulators.
    Curr Opin Rheumatol. 2009 Jul;21(4):374-9 PMID: 19412100
  29. A cytokine-mediated link between innate immunity, inflammation, and cancer.
    J Clin Invest. 2007 May;117(5):1175-83 PMID: 17476347
  30. E6-associated protein (E6-AP) is a dual function coactivator of steroid hormone receptors.
    Nucl Recept Signal. 2008 Apr 18;6:e006 PMID: 18432313
  31. Prostate cancer patients with BRCA2 mutation face poor survival.
    BMJ. 2008 Jul 10;337:a705 PMID: 18617489
  32. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study.
    J Urol. 2006 Sep;176(3):1012-6 PMID: 16890681
  33. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.
    J Urol. 2002 Jul;168(1):9-12 PMID: 12050481
  34. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer.
    Endocr Relat Cancer. 2004 Sep;11(3):459-76 PMID: 15369448
  35. Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts.
    Cancer Microenviron. 2009 Dec;2(1):9-21 PMID: 19308679
  36. Multiple signal transduction pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase in normal and tumoral target tissues.
    J Steroid Biochem Mol Biol. 2001 Jan-Mar;76(1-5):213-25 PMID: 11384880
  37. SRC-3 is required for prostate cancer cell proliferation and survival.
    Cancer Res. 2005 Sep 1;65(17):7976-83 PMID: 16140970
  38. An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients.
    Eur Urol. 2010 Feb;57(2):238-45 PMID: 19481335
  39. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone.
    Endocr Rev. 2003 Apr;24(2):152-82 PMID: 12700178
  40. DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast.
    Endocrinology. 2009 Jul;150(7):3318-26 PMID: 19342456
  41. Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?
    Nat Clin Pract Oncol. 2009 Jan;6(1):12-3 PMID: 18957947
  42. Progesterone and breast cancer.
    Womens Health (Lond). 2008 Mar;4(2):151-62 PMID: 19072517
  43. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.
    Ann Intern Med. 2000 Apr 4;132(7):566-77 PMID: 10744594
  44. Nuclear receptor coregulators in cancer biology.
    Cancer Res. 2009 Nov 1;69(21):8217-22 PMID: 19843848
  45. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer.
    Int J Cancer. 2007 Feb 15;120(4):719-33 PMID: 17163421
  46. Minireview: regulation of prostatic stem cells by stromal niche in health and disease.
    Endocrinology. 2008 Sep;149(9):4303-6 PMID: 18535102
  47. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
    Breast Cancer Res Treat. 2006 Jul;98(2):217-22 PMID: 16538529
  48. Selective aromatase inhibition for patients with androgen-independent prostate carcinoma.
    Cancer. 2002 Nov 1;95(9):1864-8 PMID: 12404279
  49. Estrogen as therapy for breast cancer.
    Breast Cancer Res. 2002;4(4):133-6 PMID: 12100736
  50. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
    Lancet. 2005 May 14-20;365(9472):1687-717 PMID: 15894097
  51. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway .
    Prostate. 2000 Feb 15;42(3):239-42 PMID: 10639195
  52. Treating prostate cancer: a rationale for targeting local oestrogens.
    Nat Rev Cancer. 2007 Aug;7(8):621-7 PMID: 17611544
  53. Reprint of: Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy.
    Hum Pathol. 2008 Feb;39(2):282-91 PMID: 18206496
  54. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer.
    Clin Cancer Res. 2003 Oct 15;9(13):4792-801 PMID: 14581350
  55. Pten in stromal fibroblasts suppresses mammary epithelial tumours.
    Nature. 2009 Oct 22;461(7267):1084-91 PMID: 19847259
  56. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years.
    J Natl Cancer Inst. 2001 Mar 21;93(6):456-62 PMID: 11259471
  57. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK.
    J Immunol. 2005 Jul 15;175(2):1197-205 PMID: 16002723
  58. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor.
    Cancer Res. 2000 Nov 1;60(21):5946-9 PMID: 11085509
  59. Clinical use of therapies targeting tumor vasculature and stroma.
    Curr Cancer Drug Targets. 2008 Sep;8(6):498-508 PMID: 18781896
  60. Steroid hormone receptor expression in male breast cancer.
    Eur J Surg Oncol. 2006 Feb;32(1):44-7 PMID: 16260112
  61. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
    Cancer Res. 2008 Aug 1;68(15):6407-15 PMID: 18676866
  62. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland.
    J Clin Invest. 2007 Dec;117(12):3988-4002 PMID: 18060036
  63. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
    J Natl Cancer Inst. 2003 Mar 5;95(5):353-61 PMID: 12618500
  64. Testosterone and the breast.
    Menopause Int. 2008 Sep;14(3):117-22 PMID: 18714077
  65. The androgen axis in recurrent prostate cancer.
    Clin Cancer Res. 2004 Jan 15;10(2):440-8 PMID: 14760063
  66. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer.
    Cancer Res. 2009 Aug 1;69(15):6131-40 PMID: 19638585
  67. Maximal androgen blockade for advanced prostate cancer.
    Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):331-40 PMID: 18471790
  68. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations.
    Clin Cancer Res. 2009 Feb 1;15(3):1112-20 PMID: 19188187
  69. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
    Oncogene. 2009 Jan 29;28(4):575-86 PMID: 18997820
  70. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
    J Clin Oncol. 2005 Jan 20;23(3):619-29 PMID: 15545664
  71. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
    J Clin Oncol. 2008 Aug 1;26(22):3727-34 PMID: 18669459
  72. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
    J Clin Oncol. 2009 Aug 10;27(23):3742-8 PMID: 19470933
  73. Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial.
    Br J Cancer. 2009 Sep 1;101(5):843-8 PMID: 19654575
  74. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression.
    Cancer Res. 2008 Jul 1;68(13):5460-8 PMID: 18593949
  75. Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence.
    Clin Cancer Res. 2009 Mar 15;15(6):2098-106 PMID: 19276281
  76. Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer.
    Oncogene. 2008 Dec 4;27(57):7180-91 PMID: 18794802
  77. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development.
    J Steroid Biochem Mol Biol. 2004 Nov;92(4):221-36 PMID: 15663986
  78. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Prostate. 2007 May 15;67(7):764-73 PMID: 17373716
  79. Prostate cancer stem cells: a new target for therapy.
    J Clin Oncol. 2008 Jun 10;26(17):2862-70 PMID: 18539965
  80. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial.
    J Urol. 2006 Sep;176(3):965-70; discussion 970-1 PMID: 16890670
  81. Nuclear receptor coregulators: cellular and molecular biology.
    Endocr Rev. 1999 Jun;20(3):321-44 PMID: 10368774
  82. A physiologic role for testosterone in limiting estrogenic stimulation of the breast.
    Menopause. 2003 Jul-Aug;10(4):292-8 PMID: 12851512
  83. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
    J Urol. 2007 Dec;178(6):2372-6; discussion 2377 PMID: 17936834
  84. Endocrine-induced regression of cancers.
    Cancer Res. 1967 Nov;27(11):1925-30 PMID: 5624120
  85. Androgens induce divergent proliferative responses in human breast cancer cell lines.
    J Steroid Biochem Mol Biol. 1995 May;52(5):459-67 PMID: 7748811
  86. Mesenchymal-epithelial interactions: past, present, and future.
    Differentiation. 2008 Jul;76(6):578-86 PMID: 18557761
  87. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    BJU Int. 2008 Dec;102(11):1531-8 PMID: 19035858
  88. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression.
    Breast Cancer Res. 2007;9(4):212 PMID: 17705880
  89. Gene expression profiling of the tumor microenvironment during breast cancer progression.
    Breast Cancer Res. 2009;11(1):R7 PMID: 19187537
  90. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study.
    J Clin Oncol. 2008 Apr 10;26(11):1824-9 PMID: 18398147
  91. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling.
    FASEB J. 2008 May;22(5):1512-20 PMID: 18055862
  92. Finasteride for prostatic disease: an updated and comprehensive review.
    Expert Opin Drug Metab Toxicol. 2008 Dec;4(12):1561-8 PMID: 19040331
  93. The dual, opposing roles of estrogen in the prostate.
    Ann N Y Acad Sci. 2009 Feb;1155:174-86 PMID: 19250203
  94. The roles of sex steroid receptor coregulators in cancer.
    Mol Cancer. 2002 Nov 14;1:7 PMID: 12473178
  95. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.
    J Clin Oncol. 1995 Jul;13(7):1572-7 PMID: 7602345
  96. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
    J Clin Oncol. 2008 Oct 1;26(28):4563-71 PMID: 18645193
  97. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003370 PMID: 17253488
  98. Interleukin-4 activates androgen receptor through CBP/p300.
    Prostate. 2009 Feb 1;69(2):126-32 PMID: 18819102
  99. Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated.
    Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3123-8 PMID: 20133657
  100. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.
    Science. 1997 Aug 15;277(5328):965-8 PMID: 9252329
  101. Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer.
    Cancer Res. 2005 Nov 15;65(22):10423-30 PMID: 16288033
  102. The influence of finasteride on the development of prostate cancer.
    N Engl J Med. 2003 Jul 17;349(3):215-24 PMID: 12824459
  103. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
    J Clin Oncol. 1996 Jun;14(6):1756-64 PMID: 8656243
  104. Estrogen--the good, the bad, and the unexpected.
    Endocr Rev. 2005 May;26(3):322-30 PMID: 15817672
  105. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients.
    Clin Cancer Res. 2003 Oct 1;9(12):4452-9 PMID: 14555518
  106. Cloning of a novel receptor expressed in rat prostate and ovary.
    Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5925-30 PMID: 8650195
  107. Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia.
    Am J Pathol. 2001 Jul;159(1):139-47 PMID: 11438462
  108. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha.
    Cancer Res. 2007 Oct 15;67(20):10087-96 PMID: 17942943
  109. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
    Cancer. 2008 Jun;112(11):2393-400 PMID: 18383517
  110. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer.
    BJU Int. 2005 May;95(7):961-2 PMID: 15839913
  111. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study.
    J Urol. 2008 Jan;179(1):152-5 PMID: 18001802
  112. Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer.
    Cancer Res. 2009 Sep 1;69(17):6865-70 PMID: 19706753
  113. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.
    Br J Cancer. 2009 Mar 10;100(5):671-5 PMID: 19223900
  114. Crucial role of cytokines in sex steroid formation in normal and tumoral tissues.
    Mol Cell Endocrinol. 2001 Jan 22;171(1-2):25-40 PMID: 11165008
  115. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    J Natl Cancer Inst. 2004 Jun 16;96(12):926-35 PMID: 15199112
  116. Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells.
    Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11256-61 PMID: 11016951
  117. CYP17 inhibition as a hormonal strategy for prostate cancer.
    Nat Clin Pract Urol. 2008 Nov;5(11):610-20 PMID: 18985049
  118. Molecular characterisation of the tumour microenvironment in breast cancer.
    Eur J Cancer. 2008 Dec;44(18):2760-5 PMID: 19026532
  119. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Cancer. 2003 Nov 1;98(9):1802-10 PMID: 14584060
  120. The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance.
    Breast Cancer Res Treat. 2009 May;115(2):289-96 PMID: 18521740
  121. Expression of androgen receptors in primary breast cancer.
    Ann Oncol. 2010 Mar;21(3):488-492 PMID: 19887463
  122. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.
    Clin Cancer Res. 2005 Jul 1;11(13):4653-7 PMID: 16000557
  123. Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
    Science. 2009 May 8;324(5928):787-90 PMID: 19359544
  124. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
    J Clin Oncol. 2004 Mar 15;22(6):1025-33 PMID: 15020604
  125. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays.
    Cancer Res. 2001 Mar 1;61(5):1919-26 PMID: 11280747
  126. Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts.
    J Steroid Biochem Mol Biol. 2009 Jul;115(3-5):126-36 PMID: 19442514
Article Info
Journal
Nature reviews. Cancer
Abbr.
Nat Rev Cancer
ISSN
1474-1768
DOI
10.1038/nrc2795
Email
gail.risbridger@med.monash.edu.au
Published
2010-03-00
Epub
2010-00-11
Pages
205-12
Language
English
Region
England
NLM ID
101124168
Subset
IM
Corrections
CommentIn
PMID: 20574451
External Links
PubMed source DOI: 10.1038/nrc2795 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2